Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy and PD-1/PD-L1 Inhibitors for Metastatic Malignant Solid Tumors After Acquired Resistance to Anti-PD1/PD-L1 Treatment

NCT07071103 is registered in ClinicalTrials.gov with Chuangzhen Chen as lead sponsor.

NCT NCT07071103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07071103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy and PD-1/PD-L1 Inhibitors for Metastatic Malignant Solid Tumors After Acquired Resistance to Anti-PD1/PD-L1 Treatment
Lead sponsor
Chuangzhen Chen
Phase
Phase 2
Overall status
Recruiting
Start date
September 26, 2025
Completion date
January 1, 2028
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistance, esophageal neoplasms malignant, immune checkpoint blockade, lung neoplasm malignant, metastatic solid cancers, radiotherapy